PDF(Sci-hub)
Abstract：
Colchicine has received renewed interest for its potential beneficial effects in secondary prevention of cardiovascular disease. This was presumed to be primarily because of its anti-inflammatory effects; however, limited data exist regarding colchicine\'s impact on other cardiovascular risk factors.
The aim of this study was to examine if colchicine\'s anti-inflammatory actions would lead to reduced circulating concentrations of oxidized low-density lipoprotein (oxLDL) in metabolically unhealthy individuals. We also examined if colchicine would improve concentrations of other atherogenic lipoprotein subfractions.
This is a secondary analysis of a double-blind, randomized, placebo-controlled pilot study in which 40 adults with metabolic syndrome were randomized to colchicine 0.6 mg or placebo twice daily for 3 months. Blood samples were collected in the fasted state. OxLDL was measured using enzyme-linked immunosorbent assay. Nuclear magnetic resonance spectroscopy was used to measure other lipoprotein particle subfraction concentrations.
Compared with placebo, colchicine reduced markers of inflammation, including C-reactive protein, erythrocyte sedimentation rate, and GlycA (P < .01). Concentrations of oxLDL (P = .019) and small LDL (P = .022) appeared significantly increased in the colchicine arm. Colchicine had no significant effect on other lipoprotein subfractions or lipoprotein particle sizes (all P > .05).
Although colchicine may have benefit in secondary prevention of cardiovascular disease in at-risk individuals, we found no evidence that these effects are because of improvements in circulating atherogenic lipoprotein particle concentrations. Further studies are needed to confirm whether colchicine increases circulating oxLDL and small LDL levels in adults with metabolic syndrome. If true, additional research is warranted to elucidate the mechanisms underlying these associations.
The aim of this study was to examine if colchicine\'s anti-inflammatory actions would lead to reduced circulating concentrations of oxidized low-density lipoprotein (oxLDL) in metabolically unhealthy individuals. We also examined if colchicine would improve concentrations of other atherogenic lipoprotein subfractions.
This is a secondary analysis of a double-blind, randomized, placebo-controlled pilot study in which 40 adults with metabolic syndrome were randomized to colchicine 0.6 mg or placebo twice daily for 3 months. Blood samples were collected in the fasted state. OxLDL was measured using enzyme-linked immunosorbent assay. Nuclear magnetic resonance spectroscopy was used to measure other lipoprotein particle subfraction concentrations.
Compared with placebo, colchicine reduced markers of inflammation, including C-reactive protein, erythrocyte sedimentation rate, and GlycA (P < .01). Concentrations of oxLDL (P = .019) and small LDL (P = .022) appeared significantly increased in the colchicine arm. Colchicine had no significant effect on other lipoprotein subfractions or lipoprotein particle sizes (all P > .05).
Although colchicine may have benefit in secondary prevention of cardiovascular disease in at-risk individuals, we found no evidence that these effects are because of improvements in circulating atherogenic lipoprotein particle concentrations. Further studies are needed to confirm whether colchicine increases circulating oxLDL and small LDL levels in adults with metabolic syndrome. If true, additional research is warranted to elucidate the mechanisms underlying these associations.
摘要：
秋水仙碱因其在心血管疾病二级预防中的潜在有益作用而重新受到关注。据推测，这主要是因为其抗炎作用；然而，关于秋水仙碱对其他心血管危险因素的影响的数据有限。
这项研究的目的是检查秋水仙碱的抗炎作用是否会导致代谢不健康个体中氧化低密度脂蛋白（oxLDL）的循环浓度降低。我们还检查了秋水仙碱是否会改善其他致动脉粥样硬化脂蛋白亚组分的浓度。
这是对双盲的二次分析，随机化，安慰剂对照试验研究,40例代谢综合征成人随机接受秋水仙碱0.6mg或安慰剂,每日2次,共3个月.在禁食状态下收集血液样品。使用酶联免疫吸附测定法测量OxLDL。核磁共振波谱用于测量其他脂蛋白颗粒亚组分浓度。
与安慰剂相比，秋水仙碱减少炎症标志物，包括C反应蛋白,红细胞沉降率,和GlycA（P<0.01）。在秋水仙碱组中，oxLDL（P=0.019）和小LDL（P=0.022）的浓度显着增加。秋水仙碱对其他脂蛋白亚组分或脂蛋白粒径无显著影响(均P>.05)。
尽管秋水仙碱在高危人群的心血管疾病二级预防中可能有益处，我们没有发现证据表明这些作用是由于循环动脉粥样硬化脂蛋白颗粒浓度的改善。需要进一步的研究来确认秋水仙碱是否会增加代谢综合征成人的循环oxLDL和小LDL水平。如果为true，需要进一步的研究来阐明这些关联的潜在机制.
这项研究的目的是检查秋水仙碱的抗炎作用是否会导致代谢不健康个体中氧化低密度脂蛋白（oxLDL）的循环浓度降低。我们还检查了秋水仙碱是否会改善其他致动脉粥样硬化脂蛋白亚组分的浓度。
这是对双盲的二次分析，随机化，安慰剂对照试验研究,40例代谢综合征成人随机接受秋水仙碱0.6mg或安慰剂,每日2次,共3个月.在禁食状态下收集血液样品。使用酶联免疫吸附测定法测量OxLDL。核磁共振波谱用于测量其他脂蛋白颗粒亚组分浓度。
与安慰剂相比，秋水仙碱减少炎症标志物，包括C反应蛋白,红细胞沉降率,和GlycA（P<0.01）。在秋水仙碱组中，oxLDL（P=0.019）和小LDL（P=0.022）的浓度显着增加。秋水仙碱对其他脂蛋白亚组分或脂蛋白粒径无显著影响(均P>.05)。
尽管秋水仙碱在高危人群的心血管疾病二级预防中可能有益处，我们没有发现证据表明这些作用是由于循环动脉粥样硬化脂蛋白颗粒浓度的改善。需要进一步的研究来确认秋水仙碱是否会增加代谢综合征成人的循环oxLDL和小LDL水平。如果为true，需要进一步的研究来阐明这些关联的潜在机制.
